Background SARS-CoV-2 vaccines currently authorized for emergency use have been highly
successful in preventing infection and lessening disease severity. The vaccines maintain …

The increasing prevalence of SARS-CoV-2 variants with mutations in the spike protein has
raised concerns that recovered individuals may not be protected from reinfection and that …

The increasing prevalence of SARS-CoV-2 variants has raised concerns regarding possible
decreases in vaccine efficacy. Here, neutralizing antibody titers elicited by mRNA-based …

DNA sequence analysis recently identified the novel SARS-CoV-2 variant B.1.526 that is
spreading at an alarming rate in the New York City area. Two versions of the variant were …

The increasing prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants with spike protein mutations raises concerns that antibodies elicited by natural …

Soluble forms of angiotensin-converting enzyme 2 (ACE2) have recently been shown to
inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We report on …

Monoclonal antibodies against the SARS-CoV-2 spike protein, notably, those developed by
Regeneron Pharmaceuticals and Eli Lilly and Company have proven to provide protection …

Highly transmissible SARS-CoV-2 variants identified in India and designated B.1.617,
Kappa (B.1.617.1), Delta (B.1.617.2), B.1.618, and B.1.36.29 contain spike mutations L452R, …

The SARS-CoV-2 lambda variant (lineage C.37) was designated by the World Health
Organization as a variant of interest and is currently increasing in prevalence in South American …

Monoclonal antibody therapy for the treatment of SARS-CoV-2 infection has been highly
successful in decreasing disease severity; however, the recent emergence of the heavily …